Key facts
- It has raised $58.8M across 8 recorded rounds; the latest was Seed Round ($385K) in May 2026.
- Notable investors include Cercano Management, Pacira BioSciences, Viscogliosi Bros..
- Spine BioPharma has filed 8 Form Ds with the SEC since 2021, most recently Jun 2026 ($385K sold to 3 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 8 rounds
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Spine BioPharma
Funding rounds
8 roundsAbout Spine BioPharma
Developer of non-surgical therapies designed to reduce pain, restore function, and slow or stop pathological spinal disease progression. The company offers a research-focused biopharmaceutical platform with clinically oriented therapies that aim to reduce pain, restore mobility, modulate pathological processes, and broaden potential treatment indications, enabling patients suffering from degenerative disc disease and related spinal conditions to access new medical options that may improve quality of life and slow disease progression.
- Sector
- Healthcare
- HQ
- New York, NY, United States
- Founded
- 2015
- Employees
- 12
- Website
- spinebiopharma.com/
- Ownership
- Privately Held (backing)
Spine BioPharma doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Spine BioPharma shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Spine BioPharma in its N-PORT filings yet. We sweep new filings monthly.